42
Participants
Start Date
September 25, 2020
Primary Completion Date
November 20, 2024
Study Completion Date
January 7, 2025
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.
Mount Sinai Hospital, New York
MedStar Heart and Vascular Institute, Washington D.C.
Mayo Clinic, Rochester
Virginia Commonwealth University, Richmond
University of North Carolina at Chapel Hill, Chapel Hill
Medical University of South Carolina, Charleston
Augusta University, Augusta
University of Alabama, Birmingham
Norton Health, Louisville
The Ohio State University, Columbus
University Hospital, Cleveland
Aurora St. Luke's Medical Center, Milwaukee
Washington University, St Louis
The University of Kansas Medical Center, Kansas City
Ochsner Louisiana State University Health, Shreveport
Baylor Scott and White Institute, Dallas
Houston Methodist Hospital, Houston
Ascension Seton Medical Center Austin, Austin
University of Arizona, Tucson
University of New Mexico, Albuquerque
UCLA, Los Angeles
University of Southern California, Los Angeles
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance
University of California San Francisco, San Francisco
UC Davis, Sacramento
Tufts University, Boston
Respira Therapeutics, Inc.
INDUSTRY